Clinical Trials Logo

Healthy Subjects clinical trials

View clinical trials related to Healthy Subjects.

Filter by:

NCT ID: NCT06248099 Not yet recruiting - Healthy Subjects Clinical Trials

Nebivolol Tablets 5 mg Relative to Nebilet Tablets 5 mg

Start date: July 9, 2024
Phase: Phase 1
Study type: Interventional

The study is to compare the rate and extent of absorption of a generic formulation with that of a reference for mulation when given as equal labeled dose. The study will be randomized, open-label, single dose, two way crossover design with two-period, two-treatment and two-sequence under fasting condition and at least 28 days washout period between the doses.

NCT ID: NCT06233266 Not yet recruiting - Healthy Subjects Clinical Trials

Ticagrelor Tablets 90 mg Relative to Originator Ticagrelor Tablets 90 mg

TIC-025-23
Start date: June 18, 2024
Phase: Phase 1
Study type: Interventional

The study is to compare the rate and extent of absorption of a generic formulation with that of a reference for mulation when given as equal labeled dose. The study will be randomized, open-label, single dose, two way crossover design with two-period, two-treatment and two-sequence under fasting condition and at least 7 days washout period between the doses.

NCT ID: NCT06233240 Not yet recruiting - Healthy Subjects Clinical Trials

Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg Relative to Originator

Start date: April 30, 2024
Phase: Phase 1
Study type: Interventional

The study is to compare the rate and extent of absorption of a generic formulation with that of a reference for mulation when given as equal labeled dose. The study will be randomized, open-label, single dose, two way crossover design with two-period, two-treatment and two-sequence under fed condition and at least 7 days washout period between the doses.

NCT ID: NCT06233227 Not yet recruiting - Healthy Subjects Clinical Trials

Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule

Start date: September 24, 2024
Phase: Phase 1
Study type: Interventional

The study is to compare the rate and extent of absorption of a generic formulation with that of a reference for mulation when given as equal labeled dose. The study will be randomized, open-label, single dose, two way crossover design with two-period, two-treatment and two-sequence under fasting condition and at least 28 days washout period between the doses.

NCT ID: NCT06233201 Not yet recruiting - Healthy Subjects Clinical Trials

Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Relative to Originator

Start date: June 4, 2024
Phase: Phase 1
Study type: Interventional

The study is to compare the rate and extent of absorption of a generic formulation with that of a reference for mulation when given as equal labeled dose. The study will be randomized, open-label, single dose, two way crossover design with two-period, two-treatment and two-sequence under fed condition and at least 7 days washout period between the doses.

NCT ID: NCT06233162 Not yet recruiting - Healthy Subjects Clinical Trials

Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets

Start date: September 3, 2024
Phase: Phase 1
Study type: Interventional

The study is to compare the rate and extent of absorption of a generic formulation with that of a reference for mulation when given as equal labeled dose. The study will be randomized, open-label, single dose, two way crossover design with two-period, two-treatment and two-sequence under fasting condition and at least 14 days washout period between the doses.

NCT ID: NCT06233149 Not yet recruiting - Healthy Subjects Clinical Trials

Esomeprazole Magnesium Dihydrate 40 mg Tablets Relative to Nexium 40 mg Tablets Under Fed Condition

Start date: October 1, 2024
Phase: Phase 1
Study type: Interventional

The study is to compare the rate and extent of absorption of a generic formulation with that of a reference for mulation when given as equal labeled dose. The study will be randomized, open-label, single dose, full replicate crossover design with four-period, two-treatment, and two-sequence under fed condition and at least 7 days washout period between the doses.

NCT ID: NCT06233097 Not yet recruiting - Healthy Subjects Clinical Trials

Esomeprazole Magnesium Dihydrate 40 mg Tablets Relative to Nexium 40 mg Tablets Under Fasting Condition

Start date: August 29, 2024
Phase: Phase 1
Study type: Interventional

The study is to compare the rate and extent of absorption of a generic formulation with that of a reference for mulation when given as equal labeled dose. The study will be randomized, open-label, single dose, two way crossover design with two-period, two-treatment and two-sequence under fasting condition and at least 7 days washout period between the doses

NCT ID: NCT06233084 Not yet recruiting - Healthy Subjects Clinical Trials

Desogestrel Tablets (0.075 mg) Relative to Originator Desogestrel Tablets (0.075 mg)

Start date: July 16, 2024
Phase: Phase 1
Study type: Interventional

The study is to compare the rate and extent of absorption of a generic formulation with that of a reference for mulation when given as equal labeled dose. The study will be randomized, open-label, single dose, two way crossover design with two-period, two-treatment and two-sequence under fasting condition and at least 28 days washout period between the doses.

NCT ID: NCT06233071 Recruiting - Healthy Subjects Clinical Trials

Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) Tablets Relative to Yaz®

Start date: February 13, 2024
Phase: Phase 1
Study type: Interventional

The study is to compare the rate and extent of absorption of a generic formulation with that of a reference for mulation when given as equal labeled dose. The study will be randomized, open-label, single dose, two way crossover design with two-period, two-treatment and two-sequence under fasting condition and at least 28 days washout period between the doses.